First Lady Of The United States Of America Has The key To Unlock A Breast Cancer Cure

Barron's Medical Journal Reporting From George Bush Library Dallas, Texas And The University Of Texas Medical School Houston


The First Lady Of The United States Of America Has The key To Unlock A Breast Cancer Cure:


Dallas, TX ( AP ) , May 29, 2013 (GLOBE NEWSWIRE) –---- The First Lady Of The United States Of America Michelle Obama Has The key To Unlock A Breast Cancer Cure. Barron’s Medical Journal Research indicates that a breast cancer cure would be a reality 71 percent faster, provided Michelle Obama would chair a committee to ask the question where we are on a cure for breast cancer.Barron’s Medical Journal research also found that one of the major stumbling blocks for a breast cancer cure is the lack of collaboration and communication between the United States Universities, Genomic Scientist and the Pharmaceutical industry.

The next concern is genomics science researching cancer is too broad. Too many scientists are trying to find a cure for too many diseases. What if for the next eight months 70 percent of the Scientists that benefits from Federal National Institute of Health grants would focus one hundred percent of that time on a cure for a breast cancer cure.

Angelina Jolie has drawn the attention of the American public with her announcement that she has had a procedure to stop breast cancer from happening to her and the Surpreme Court making a major decision on BRCA1 and BRCA2.

(Hereditary Breast Ovarian Cancer Syndrome (BRCA1 / BRCA2) BRCA1 Mutation

- Average 65 percent lifetime risk for breast cancer

- 40 percent to 60 percent lifetime risk for second breast cancer (not reappearance of first tumor)

- Average 39 percent lifetime risk for ovarian cancer

-increased risk for other cancer types, such as prostate cancer BRCA2 Mutation

- Average 45 percent lifetime risk for breast cancer (in females)

- 6 percent lifetime risk for breast cancer (in males)

- Average 11 percent lifetime risk for ovarian cancer

- increased risk for other cancer types, such as pancreatic, prostate, laryngeal, stomach cancer, and melanoma

It is going to take most of the scientist and Medical Communities to develop a cure. Having one company Myriad own the primary genes, BRCA1 and BRCA2 genes to accomplish a cure is like saying Ford is the only company that can make automobiles. Barron’s Medical Journal says that it is as simple as the law of supply and demand the more companies that can develop a cure with our Mothers, Sisters, and Daughters genes, the faster a complete cure will be developed. To help you understand the issues here is some background on the matter.

Barron’s Medical Journal reports that the Surpreme Court remanded the case of The Association for Molecular Pathology, et al., v. Myriad Genetics, Inc., et al (Docket No. 11-725) to the Federal Circuit Court of Appeals. The question is should one company have all the rights to a gene that is the core of breast cancer ? Docket No. 11-725 is the Surpreme Court case that concerns the patents held on the BRCA1 and BRCA2 genes, which are both closely associated with the risk of developing breast and ovarian cancer. The genes were isolated by Myriad Genetics and the University of Utah, and Myriad manufactures the only test currently available to identify the two genes. In July 2011, the appellate court ruled 2-to-1 in favor of Myriad, stating that the genes could be patented because they did not occur in isolation in nature.

This reversed a decision made by a US District Court in New York in March 2010 that stated that Myriad could not patent the genes. The Surpreme Court made a decision regarding patents on molecular testing that prompted the nation’s highest judicial authority to ask the appellate court to reconsider its previous decision with regard to Myriad: The case of Mayo Collaborative Services, Mayo Medical Laboratories, et al., v. Prometheus Laboratories, Inc. (Docket No. 10-1150) concerned a blood test used to identify thiopurine metabolites formed when the body breaks down thiopurine drugs taken by patients with gastrointestinal and nongastrointestinal autoimmune diseases to determine whether a prescribing physician should raise or lower the drug dosage. Breast Cancer Patients Can Now Benefit From Every Scientist In The World Working On A Cure Sam Houston Our Science NoteBook is BRCA1 BRCA2 Compliant Sam Houston is clear to sale it's Science NoteBook to Breast Cancer Doctors. The Surpreme Court has ruled on Myriad Genetics Inc. case. The patent protection, Patent protection is important for companies that are focusing on personalized medicine, including Sam Houston Biotech Myriad Genetics Inc. (MYGN) and Novartis AG. (NOVN) The field involves determining whether a patient is genetically susceptible to a particular disease or would be especially responsive to certain medicine. On 26 March, the US Surpreme Court handed down a short summary disposition as the latest installment in a long-running case that questions whether human genes can be patented.

Comments

In order to comment on BlogHer.com, you'll need to be logged in. You'll be given the option to log in or create an account when you publish your comment. If you do not log in or create an account, your comment will not be displayed.